Despite a decade of biologic and targeted therapy development, many people with inflammatory bowel disease (IBD) still cycle through flares, treatment escalation and loss of response, according to discussions at Digestive Disease Week (DDW) 2026. Experts speaking at the meeting argued that achieving durable, deep remission, rather than simply controlling acute symptoms, should become the central goal of IBD care.
Background Context
IBD, encompassing Crohn’s disease and ulcerative colitis, is typically managed with a growing range of biologic and targeted therapies aimed at reducing inflammation and preventing complications such as hospitalisation and surgery. Even so, real-world experience suggests that a substantial proportion of patients do not reach lasting disease control. Clinicians attending DDW 2026 described a recurring pattern in which patients respond initially to therapy, then lose that response over time, prompting further treatment changes and, in many cases, a return of active disease.
Key Findings
According to reporting on discussions at DDW 2026, experts emphasised that selecting an appropriate advanced therapy early, matched to disease severity and individual patient needs, can support more rapid and sustained remission, while lowering the likelihood of hospital admission, emergency care and surgery. Researchers described ongoing work targeting specific immune signalling pathways with the aim of promoting healing of the intestinal lining rather than symptom suppression alone.
Alongside treatment selection, educational sessions covered in Medscape Education material highlighted several supporting strategies. These included structuring sensitive conversations about weight management into routine IBD consultations, given evidence that obesity can influence disease course and response to treatment. Guidance was also presented on incorporating biosimilar medicines into care pathways using evidence-based approaches, and on identifying suitable patients with ulcerative colitis for sphingosine-1-phosphate (S1P) receptor modulator therapy, including when treatment should begin and how patients should be monitored. Experts further noted that coordinated, interdisciplinary teams involving gastroenterologists, nurses and other specialists were associated with improved management of complex, chronic inflammatory disease.
Clinical Relevance
For clinicians and patients, the discussions reinforce a shift away from reactive flare management towards proactive, individualised treatment planning from diagnosis onward. If early, well-matched advanced therapy can reduce reliance on corticosteroids and lower rates of hospitalisation and surgery, as suggested at DDW 2026, this has direct implications for long-term quality of life. The parallel emphasis on comorbidity management, particularly weight, and on interdisciplinary care delivery points to a broader model of IBD management that extends beyond medication choice alone, though the source material describes expert perspective and educational guidance rather than new trial data.
Reference
The source material provided is a news digest summarising expert commentary and educational content presented at Digestive Disease Week 2026, as reported by Drug Discovery News and Medscape Education. No specific peer-reviewed journal article, clinical trial, or registry record was identified within the source material to serve as a primary citation. Readers seeking the underlying evidence should consult the original DDW 2026 conference proceedings and the cited Medscape Education and Drug Discovery News reports directly.
This article is a journalistic summary for informational purposes only. It does not constitute clinical advice or a recommendation to alter treatment decisions.